Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Radiation Injuries 1Oropharyngeal Neoplasms 1Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Cholangiocarcinoma 1Cervical Cancer Susceptible Population Classification 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 21Cisplatin 16durvalumab 12lenvatinib 11Oxaliplatin 11pembrolizumab 6Liver Transplantation 4Leucovorin 4Floxuridine 4tislelizumab 3Nivolumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Fluorouracil 3Drug Therapy 3Capecitabine 3Biopsy 3tremelimumab 2pemigatinib 2olaparib 2ivosidenib 2irinotecan sucrosofate 2apatinib 2Taxes 2Specimen Handling 2Injections 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cholangiocarcinoma × Base Sequence × Clear all
NCT06648057 2026-03-18

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

CHA University

Recruiting
100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡